AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Whitehawk Therapeutics Inc
Video analysis: WHWK
All videosNo video analysis for this stock yet. Request one from our team.
News: WHWK
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC).
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences: Cantor Global Healthcare Conference 2026 – management will participate in investor meetings on September 9, 2026.
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
The mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments of $190.0 million as of June 30, 2026, anticipated to fund operations into 2H 2028 MORRISTOWN, N.J., Aug. 6, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended June 30, 2026, and provided recent corporate highlights.
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
BOSTON & MORRISTOWN, N.J.--(BUSINESS WIRE)-- #ADC--Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resultin.
